Publications by Maximilien Murone

In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103

Freddy Radtke, Rajwinder Lehal, Maximilien Murone, Andrea Rinaldi

WILEY2022

Direct targeting of NOTCH transcription complex by a novel small molecule CB-103 circumvents dose-limiting toxicities associated with pan-NOTCH inhibitors

Freddy Radtke, Jelena Zaric, Rajwinder Lehal, Maximilien Murone, Michele Vigolo, Charlotte Marie Urech-Varenne

AMER ASSOC CANCER RESEARCH2019

Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor targeting the NOTCH transcription complex

Freddy Radtke, Rajwinder Lehal, Maximilien Murone

Oxford University Press2018

Characterization and profiling of CB-103, a novel small-molecule protein-protein interaction inhibitor targeting the NOTCH transcription complex

Freddy Radtke, Rajwinder Lehal, Maximilien Murone, Michele Vigolo, Charlotte Marie Urech-Varenne

AMER ASSOC CANCER RESEARCH2018

The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34(+) Stem/Progenitor Cells

Michel Aguet, Stefania Rigotti, Maximilien Murone, Andres McAllister

Acute myelogenous leukemia (AML) is initiated and maintained by leukemia stem cells (LSC). LSCs are therapy-resistant, cause relapse, and represent a major obstacle for the cure of AML. Resistance to therapy is often mediated by aberrant tyrosine kinase (T ...

Amer Assoc Cancer Research2017

Pharmacological Activity Of Cb-103-An Oral Pan-Notch Inhibitor With A Novel Mode Of Action

Freddy Radtke, Manuel Bauer, Rajwinder Lehal, Maximilien Murone

Ferrata Storti Foundation2017

Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor with a novel mode of action

Freddy Radtke, Manuel Bauer, Rajwinder Lehal, Maximilien Murone

Oxford Univ Press2017